Welcome to the e-CCO Library!

P560: Curcumin-QingDai combination for patients with active ulcerative colitis: A randomized double-blinded placebo-controlled trial
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Ben-Horin, S.(1);Salomon, N.(1)*;Karampekos, G.(2);Viazis, N.(2);Lahat, A.(1);Ungar, B.(1);Eliakim, R.(1);Kriger-Sharabi, O.(3);Reiss-Mintz, H.(4);Yanai, H.(5);Dotan, I.(6);Zittan, E.(7);Maharshak, N.(8);Hirsch, A.(9);Weitman, M.(10);Mantzaris, G.J.(2);Kopylov, U.(1);
Created: Friday, 14 July 2023, 11:05 AM
P560: Granulocyte–monocyte apheresis combination therapy after loss of response to anti-TNF drugs
Year: 2018
Source: ECCO '18 Vienna
Authors:

I. Rodríguez-Lago1*, L. Sempere2, A. Gutiérrez2,3, B. Beltrán4, E. Saez4, E. Hinojosa5, M. Mora5, F. Cañete6, M. Mañosa6, S. Khorrami7, D. Ginard7, J.L. Cabriada1

Created: Thursday, 21 February 2019, 9:14 AM
P560: Multi-centric randomised study comparing interventional vs. non-interventional treatment for anal fistulas in patient with Crohn’s disease and adalimumab treatment
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

L. Abramowitz1, D. Bouchard2, L. Siproudhis3, F. Pigot*2, P. Roumeguere-Blond4, H. Pillant5, B. Vinson-Bonnet6, J-L. Faucheron7, A. Senejoux8, G. Bonnaud9, G. Meurette10, C. Train11, G. Staumont12

Created: Friday, 22 February 2019, 9:41 AM
P560: Trough levels at induction: impact on long term response when re-initiating infliximab
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Liefferinckx C.*1, Minsart C.2, Toubeau J.-F.3, Cremer A.4, Amininejad L.4, Quertinmont E.2, Devière J.4, Gils A.5, Van Gossum A.4, Franchimont D.4

Created: Wednesday, 20 February 2019, 10:36 AM
P561 The management of Crohn’s disease (CD) patients post ileocaecal resection: a multicentre, regional audit in Northern England
Year: 2020
Source:

ECCO'20 Vienna

Authors:

S. BATCHELOR1, A. Speight2, Gastroenterology Research and Audit for Northern Trainees

Created: Thursday, 30 January 2020, 10:12 AM
P561: A comparison of medication adherence and persistence between intravenous biologics and oral small-molecule therapies
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Kane1, K. Moran2, K. Null2, Z. Huang2, T. Lissoos2*

Created: Thursday, 21 February 2019, 9:14 AM
P561: Can we predict adherence to treatment in IBD patients?
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Naftali T.*1, Ein Dor A.2,3, Ruhimovich N.4, Shitrit A.B.5, Sklerovsky Benjaminov F.2,4, Matalon S.2,3, Shirin H.3,6, Konikoff F.M.1,2, Broide E.3,6

Created: Wednesday, 20 February 2019, 10:36 AM
P561: Clinical utility of therapeutic drug monitoring of adalimumab using a point of care test
Year: 2022
Source: ECCO'22
Authors: Stevens, T.(1);Teichert, C.(1);Volkers, A.(1);Mostafavi Montazeri, N.(1);Bahur, B.(2);Bray, K.(3);D'Haens, G.(1);
Created: Friday, 11 February 2022, 3:56 PM
P561: Impact of ustekinumab TDM on clinical practice: a multi-centre, prospective, cross-sectional observational trial—mUST-Decide
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

B. Bressler*1, D. Dajnowiec2, M. Williamson3, K. Karra3, G. Long-Long4, B. Sattin3, W. Afif5

Created: Friday, 22 February 2019, 9:41 AM
P561: Risk of stoma formation in patients with Crohn's perianal fistulas over a two decades period. A cohort study from a tertiary referral center.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Bislenghi, G.(1)*;Baldi, C.(1);Ferrante, M.(2);Sabino, J.(2);Verstockt, B.(2);Wolthuis, A.(1);Vermeire, S.(2);D'Hoore, A.(1);
Created: Friday, 14 July 2023, 11:05 AM
P561: Ulcerative Colitis Endoscopic Index of Severity (UCEIS) and Mayo Endoscopic Score (MES) in predicting the therapeutic effect of mesalazine in UC patients.
Year: 2021
Source: ECCO'21 Virtual
Authors: Wu, L.(1);Zhang, Y.(1);Cao, Q.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P562 5-ASA in ulcerative colitis: Are they really needed in the biological therapy era?
Year: 2020
Source:

ECCO'20 Vienna

Authors:

C. Arieira1,2,3, F. Dias de Castro1,2,3, T. Cúrdia Gonçalves1,2,3, M.J. Moreira1,2,3, J. Cotter1,2,3

Created: Thursday, 30 January 2020, 10:12 AM
P562: A Phase 1 Study Evaluating the Effect of Coadministration of Etrasimod on the Pharmacokinetics and Pharmacodynamics of a Monophasic Oral Contraceptive in Healthy Female Volunteers
Year: 2022
Source: ECCO'22
Authors: Lee, C.(1);Tang , Y.(1);Villa-Caballero, L.(2);Liu , K.(3);Randle , A.(4);Grundy , J.(1);
Created: Friday, 11 February 2022, 3:56 PM
P562: Real world effectiveness and safety of ozanimod: One-year follow-up from a large tertiary center
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Cohen, N.A.(1)*;Choi, D.(1);Garcia, N.(1);Choi, N.(1);Picker, E.(1);Krugliak-Cleveland, N.(1);Cohen, R.(1);Dalal, S.(1);Sakuraba, A.(1);Pekow, J.(1);Rubin, D.(1);
Created: Friday, 14 July 2023, 11:05 AM
P562: Real-life infliximab trough levels among inflammatory bowel disease patients on maintenance therapy: should we redefine therapeutic range based on inflammatory load?
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Lobaton T.*1, Cañete F.1, Teniente A.2, Cabre E.1,3, Mañosa M.1, Martínez E.2, Domènech E.1,3

Created: Wednesday, 20 February 2019, 10:36 AM
P562: Role, efficacy and safety of budesonide multi-matrix in ulcerative colitis in real life: A study in three Italian third-level centres
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Landi1*, N. Mezzina2, S. Carmagnola2, M. Bosani3, E. Filippi4, L. Pastorelli4, S. Grillo1, A. Massari2, A. Cassinotti2, P. Moulteni2, A. Dell'Era2, S. Ardizzone2, G. Maconi2

Created: Thursday, 21 February 2019, 9:14 AM
P562: Treatment of older inflammatory bowel disease patients; steroid use and escalation to steroid sparing therapy
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

V. Asscher*1, N. Provoost1, L. Meijer1, A. van der Meulen-de Jong1, F. van Deudekom2, S. Mooijaart2,3, J. Maljaars1

Created: Friday, 22 February 2019, 9:41 AM
P562: Web-based questionnaire survey about self-management for patients with Inflammatory Bowel Disease in Japan
Year: 2021
Source: ECCO'21 Virtual
Authors: Nagahori, M.(1);Imai, T.(2);Tairaka, A.(2);
Created: Wednesday, 2 June 2021, 4:12 PM
P563 Shared decision-making in pregnancy in inflammatory bowel disease: Design of a pregnancy in IBD decision aid (PIDA)
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A.J. Williams1, Y. Leung2, K. O’Connor3, V. Huang3

Created: Thursday, 30 January 2020, 10:12 AM
P563: Association between smoking status and the efficacy and safety of tofacitinib in patients with Ulcerative Colitis: Data from the tofacitinib clinical programme
Year: 2022
Source: ECCO'22
Authors: Rubin, D.T.(1);Torres, J.(2);Regueiro, M.(3);Reinisch, W.(4);Prideaux, L.(5);Kotze, P.G.(6);Tan, F.H.(7);Gardiner, S.(8);Mundayat, R.(8);Cadatal, M.J.(9);Ng, S.(10);
Created: Friday, 11 February 2022, 3:56 PM